These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 25492409)
1. Formulation and stability of cytokine therapeutics. Lipiäinen T; Peltoniemi M; Sarkhel S; Yrjönen T; Vuorela H; Urtti A; Juppo A J Pharm Sci; 2015 Feb; 104(2):307-26. PubMed ID: 25492409 [TBL] [Abstract][Full Text] [Related]
2. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients. Jorgensen L; Hostrup S; Moeller EH; Grohganz H Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792 [TBL] [Abstract][Full Text] [Related]
3. Analytical Techniques for Structural Characterization of Proteins in Solid Pharmaceutical Forms: An Overview. Bolje A; Gobec S Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33920461 [TBL] [Abstract][Full Text] [Related]
6. Hydrogen-deuterium exchange mass spectrometry as an emerging analytical tool for stabilization and formulation development of therapeutic monoclonal antibodies. Majumdar R; Middaugh CR; Weis DD; Volkin DB J Pharm Sci; 2015 Feb; 104(2):327-45. PubMed ID: 25354868 [TBL] [Abstract][Full Text] [Related]
7. Formulations strategies for biopharmaceuticals--ensuring success to market. Atkinson EM; Klum W IDrugs; 2001 May; 4(5):557-60. PubMed ID: 16012901 [TBL] [Abstract][Full Text] [Related]
8. Hurdles and leaps for protein therapeutics. Kozlowski S; Cherney B; Donnelly RP Ann N Y Acad Sci; 2009 Dec; 1182():146-60. PubMed ID: 20074283 [TBL] [Abstract][Full Text] [Related]
9. The immunogenicity of therapeutic cytokines. Herzyk DJ Curr Opin Mol Ther; 2003 Apr; 5(2):167-71. PubMed ID: 12772507 [TBL] [Abstract][Full Text] [Related]
10. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Wright JF; Qu G; Tang C; Sommer JM Curr Opin Drug Discov Devel; 2003 Mar; 6(2):174-8. PubMed ID: 12669452 [TBL] [Abstract][Full Text] [Related]
11. Formulation, stability, and delivery of live attenuated vaccines for human use. Burke CJ; Hsu TA; Volkin DB Crit Rev Ther Drug Carrier Syst; 1999; 16(1):1-83. PubMed ID: 10099898 [TBL] [Abstract][Full Text] [Related]
12. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428 [TBL] [Abstract][Full Text] [Related]
13. Rational design to biologics development: The polysorbates point of view. Brovč EV; Mravljak J; Šink R; Pajk S Int J Pharm; 2020 May; 581():119285. PubMed ID: 32240804 [TBL] [Abstract][Full Text] [Related]
14. Investigation on formulation and preparation of adenovirus encoding human endostatin lyophilized powders. Chen S; Guo D; Guo B; Liu J; Shen Y; Xu X; Huang W; Guo S Int J Pharm; 2012 May; 427(2):145-52. PubMed ID: 22234038 [TBL] [Abstract][Full Text] [Related]
15. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Kumru OS; Joshi SB; Smith DE; Middaugh CR; Prusik T; Volkin DB Biologicals; 2014 Sep; 42(5):237-59. PubMed ID: 24996452 [TBL] [Abstract][Full Text] [Related]
20. Stability of nanosuspensions in drug delivery. Wang Y; Zheng Y; Zhang L; Wang Q; Zhang D J Control Release; 2013 Dec; 172(3):1126-41. PubMed ID: 23954372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]